Sanofi aims to boost competition in the atopic dermatitis market, following Dupixent's success, with new treatments like ...

Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

Atopic dermatitis, or eczema ... your doctor or dermatologist may recommend treatments such as: medications to reduce allergies and itching, such as antihistamines topical creams with a steroid ...

Tofacitinib etocomil ointment 1.0% has proven effective in treating mild-to-moderate atopic dermatitis, achieving significant ...

Winter season can trigger symptoms of atopic dermatitis by causing the skin to become dry and itchy in the cold weather. It ...

People with eczema usually experience flare-ups during the winter season. During these periods, symptoms become worse and ...

Shaperon secures phase 2 trials for atopic dermatitis treatment Nugel after positive review Shaperon obtains approval for ...

As we increase the number of patients, we remain excited by the outlook for our Phase 1 clinical trial of soquelitinib for ...

The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...